A study of Cytomegalovirus-specific T-cell therapy for the treatment of cytomegalovirus infection

Trial Profile

A study of Cytomegalovirus-specific T-cell therapy for the treatment of cytomegalovirus infection

Planning
Phase of Trial: Phase III

Latest Information Update: 11 May 2016

At a glance

  • Drugs Cytomegalovirus-specific T-cell therapy Atara/MSKCC (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Atara Biotherapeutics
  • Most Recent Events

    • 11 May 2016 New trial record
    • 05 May 2016 According to an Atara Biotherapeutics media release, the company plans to discuss clinical trial design for Cytomegalovirus Cytotoxic T-Lymphocyte (CMV-CTLs) with FDA this year and intends initiate this trial in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top